SwissPKcdw - A clinical data warehouse for the optimization of pediatric dosing regimens

Roland Goers1, Diana Coman Schmid2, Vera F Jäggi3

  • 1Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.

Insights

The Swiss Pharmacokinetics Clinical Data Warehouse (SwissPKcdw) project addresses the lack of pediatric drug dosage information by enabling secure data sharing for pharmacokinetic modeling. This infrastructure supports research by integrating clinical data for improved pediatric pharmacotherapy.

Area of Science:

  • Pharmacokinetics
  • Clinical Data Management
  • Pediatric Pharmacology

Background:

  • Limited pharmacokinetic data exists for pediatric patients, hindering accurate drug dosage recommendations.
  • Existing clinical trial data primarily focuses on adult populations.
  • Pharmacokinetic (PK) modeling offers a potential solution to bridge this data gap.

Purpose of the Study:

  • To establish a secure data infrastructure, the Swiss Pharmacokinetics Clinical Data Warehouse (SwissPKcdw), for pediatric pharmacokinetic research.
  • To facilitate secure data sharing and collaboration between healthcare providers and academic researchers.
  • To enable the use of routinely collected clinical data for PK modeling in pediatric populations.

Main Methods:

  • Implementation of a secure Clinical Data Warehouse (CDW) within the BioMedIT network.
  • Development of a regulatory framework for data transfer and utilization.
  • Utilizing modular, containerized, and open-source components for flexibility and reusability.
  • Integration of data from various providers and researchers.

Main Results:

  • Successful implementation of the SwissPKcdw infrastructure through interprofessional collaboration.
  • Demonstration of a real-world use case involving pediatric blood sample analysis for genetic polymorphisms.
  • Aggregation and analysis of genetic polymorphism data with health-related patient data within the SwissPKcdw.
  • Validation of the secure data environment for collaborative research.

Conclusions:

  • The SwissPKcdw provides a robust and secure platform for pediatric pharmacokinetic research.
  • The infrastructure enables the integration of real-world clinical data for PK modeling.
  • This collaborative approach enhances the availability of essential information for pediatric drug therapy.
  • The modular design allows for adaptation to similar data integration and analysis projects.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
36
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
19
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
23
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
27
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
32
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
23